LYSOMAX

This brand name is authorized in Nigeria.

Active ingredients

The drug LYSOMAX contains one active pharmaceutical ingredient (API):

1	Azithromycin UNII JTE4MNN1MD - AZITHROMYCIN MONOHYDRATE
	Azithromycin is a macrolide antibiotic belonging to the azalide group. The molecule is constructed by adding a nitrogen atom to the lactone ring of erythromycin A. The mechanism of action of azithromycin is based upon the suppression of bacterial protein synthesis by means of binding to the ribosomal 50S sub-unit and inhibition of peptide translocation.
	Read more about Azithromycin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-7009	Capsule	LYSOMAX CAPSULES 250MG CAP 250 mg 16CAPSULES	63 RNW-PP-263216 LYSOMAX CAPSULES 250MG AZITHROMYCIN 250MG CAPSULES Azithromycin 250mg , Excipients Lactose Monohydrate Sodium Starch Glycollate Microcrystalline Cellulose Povidone Isopropyl Alcohol Magnesium Stearate Purified Talc Cross Carmillose Sodium Methylene Chloride B4-7009 Drugs Imported Products 16CAPSULES Prescription Only Medicine (POM) 5/4/2022 LYSOPLUS HEALTHCARE LIMITED, BEHIND UNION BANK,OPPOSITE LGEA PRIMARY SCHOOL,NEW NYANYA NASSARAWA STATE. 0 regulatorylysoplus@gmail.com DUPEN LABORATORIES PVT.LTD, C1-49&36,Degam Road,IndustrialTownship,Vapi 396195,district valsad,state ofGujarat,India, India	25/05/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01FA10	Azithromycin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01F Macrolides, lincosamides and streptogramins → J01FA Macrolides
Discover more medicines within J01FA10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-7009